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PACING
Atrioventricular Synchronous Pacing
Using a Leadless Ventricular Pacemaker
Results From the MARVEL 2 Study
Clemens Steinwender, MD,a,b Surinder Kaur Khelae, MD,c Christophe Garweg, MD,d Joseph Yat Sun Chan, MD,e
Philippe Ritter, MD,f Jens Brock Johansen, MD, PHD,g Venkata Sagi, MD,h Laurence M. Epstein, MD,i
Jonathan P. Piccini, MD, MHS,j Mario Pascual, MD,k Lluis Mont, MD,l Todd Sheldon, MS,m Vincent Splett, MS,m
Kurt Stromberg, MS,m Nicole Wood, BS,m Larry Chinitz, MDn
ABSTRACT
OBJECTIVES This study reports on the performance of a leadless ventricular pacemaker with automated, enhanced
accelerometer-based algorithms that provide atrioventricular (AV) synchronous pacing.
BACKGROUND Despite many advantages, leadless pacemakers are currently only capable of single-chamber ventric-
ular pacing.
METHODS The prospective MARVEL 2 (Micra Atrial tRacking using a Ventricular accELerometer 2) study assessed the
performance of an automated, enhanced accelerometer-based algorithm downloaded to the Micra leadless pacemaker
for up to 5 h in patients with AV block. The primary efficacy objective was to demonstrate the superiority of the algorithm
to provide AV synchronous (VDD) pacing versus VVI-50 pacing in patients with sinus rhythm and complete AV block. The
primary safety objective was to demonstrate that the algorithm did not result in pauses or heart rates of >100 beats/min.
RESULTS Overall, 75 patients from 12 centers were enrolled; an accelerometer-based algorithm was downloaded to
their leadless pacemakers. Among the 40 patients with sinus rhythm and complete AV block included in the primary
efficacy objective analysis, the proportion of patients with$70% AV synchrony at rest was significantly greater with VDD
pacing than with VVI pacing (95% vs. 0%; p < 0.001). The mean percentage of AV synchrony increased from 26.8%
(median: 26.9%) during VVI pacing to 89.2% (median: 94.3%) during VDD pacing. There were no pauses or episodes of
oversensing-induced tachycardia reported during VDD pacing in all 75 patients.
CONCLUSIONS Accelerometer-based atrial sensing with an automated, enhanced algorithm significantly improved AV
synchrony in patients with sinus rhythm and AV block who were implanted with a leadless ventricular pacemaker. (Micra
Atrial Tracking Using a Ventricular Accelerometer 2 [MARVEL 2]; NCT03752151). (J Am Coll Cardiol EP 2020;6:94–106)
© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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From the aDepartment of Cardiology, Kepler University Hospital, Linz, Austria; bDepartment of Cardiology, Paracelsus Medical
University Salzburg, Salzburg, Austria; cDepartment of Electrophysiology, Institut Jantung Negara, Kuala Lumpur, Malaysia;
dDepartment of Cardiovascular Sciences, Department of Cardiology, University Hospitals Leuven, Leuven, Belgium; eDepartment
of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong; fDepartment of
Electrophysiology and Cardiac Stimulation, Hôpital Haut- Lévêque – CHU de Bordeaux, Pessac, France; gDepartment of Cardi-
ology, Odense University Hospital, Odense, Denmark; hBaptist Heart Specialists, Baptist Medical Center Jacksonville, Florida;
iDepartment of Electrophysiology, North Shore University Hospital, Manhasset, New York; jDivision of Cardiology, Duke Uni-
versity Medical Center and Duke Clinical Research Institute, Durham, North Carolina; kMiami Cardiac & Vascular Institute, Baptist
Hospital, Miami, Florida; lInstitut Clinic Cardiovascular (ICCV), Hospital Clínic, Universitat de Barcelona, Catalonia, Barcelona,
Spain; mMedtronic, Inc., Mounds View, Minnesota; and the nLeon H. Charney Division of Cardiology, NYU Langone Medical
Center, New York, New York. TheMARVEL 2 studywas funded byMedtronic, Inc. Dr. Steinwender has been amember of the Advisory
J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 6 , N O . 1 , 2 0 2 0
ª 2 0 2 0 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E AM E R I C A N
C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .
P ermanent cardiac pacing has provided sub-stantial benefits for millions of patients withbradyarrhythmias since its introduction in the
1950s. For many decades, cardiac pacing has been
exclusively performed by systems consisting of subcu-
taneously implanted pulse generators with $1 trans-
venous leads. However, approximately 1 in 8 patients
treated with these traditional pacing systems experi-
ences a complication attributed to the pacemaker
pocket or leads, such as hematoma, pneumothorax, hemo-
thorax, lead dislodgement, lead failure, or infection (1).
Leadless pacemakers were developed to overcome
pocket- and lead-related complications. Results from
the Micra Transcatheter Pacing Study and Micra Post
Approval Registry demonstrated a high implantation
success rate and a low major complication rate, with a
>60% reduction in complications versus transvenous
pacemakers (2–4). These encouraging results have led
to an increased interest in a broader use of leadless
pacemakers; however, currently available leadless
pacemakers only provide single-chamber ventricular
rate responsive pacing.
Use of transvenous single-chamber ventricular
pacemakers is limited to <15% of the pacemaker pop-
ulation (5). Patients with sinus rhythm and atrioven-
tricular (AV) block have been shown to benefit from
dual-chamber pacemakers that can provide AV syn-
chrony (6–8). Previous proof-of-concept studies tested
the performance of an AV synchronous algorithm
downloaded into an already implanted Micra device
(Model MC1VR01; Medtronic, Inc, Minneapolis, Min-
nesota) that detected atrial contractions using the
device’s built-in 3-axis accelerometer. Results
from early feasibility studies demonstrated that
accelerometer-based atrial sensing was
feasible and significantly improved AV syn-
chrony in patients with AV block and a Micra
single-chamber leadless pacemaker implan-
ted in the right ventricle (9,10). Based upon
results from the MARVEL (Micra Atrial
tRacking using a Ventricular accELerometer)
study, enhancements were made to the algo-
rithm, including automated programming
features and mode switching algorithms to
accommodate changes in patient rhythm and activity.
We report on the performance of this enhanced algo-
rithm to provide AV synchronous pacing in patients
with persistent third-degree (complete) AV block and
normal sinus rhythm implanted with a Micra leadless
pacemaker in the right ventricle.
METHODS
STUDY DESIGN. The MARVEL 2 study was a prospec-
tive, nonrandomized multicenter clinical trial. The
primary aim of the MARVEL 2 study was to confirm the
ability of an enhanced downloadable algorithm
(hereafter referred to as the MARVEL 2 algorithm) to
provide AV synchronous pacing by mechanically
sensing atrial contractions via the accelerometer signal
(VDD pacing) from a Micra leadless pacemaker
implanted in the right ventricle. A detailed description
of the algorithm is provided in the Online Appendix.
Briefly, the algorithm uses signal components from the
Micra accelerometer corresponding to passive ven-
tricular filling (A3) and atrial contraction (A4) to pro-
vide AV synchronous pacing (Online Figure S1). In
addition, 2 mode switching algorithms enable auto-
matic switching to VVI-40 and VVIR pacing. Approval
of the study protocol by local ethics committees and
SEE PAGE 107
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national regulatory agencies was sought at each
participating institution. All patients provided written
informed consent.
PATIENTS AND PROCEDURES. The MARVEL 2 study
enrolled patients with a history of AV block (including
patients with normal sinus function and complete AV
block) who were age 18 years or older and were pre-
viously implanted or undergoing implantations
(newly implanted patients) with a Micra pacemaker
that had a remaining projected device longevity of $6
years. Following informed consent, baseline proced-
ures were performed, and medical history obtained.
Most enrolled patients completed the study pro-
cedures during a single study visit. However, patients
who enrolled in the study at the time of their Micra
implantation (newly implanted patients) had the al-
gorithm downloaded and completed the study pro-
cedures after Micra implantation, but before hospital
discharge (pre-hospital discharge) and approximately
1-month post-implantation. At the study visit(s), the
algorithm was downloaded into the patient’s implan-
ted device, and a specialized Holter monitor capable of
storing accelerometer waveforms, electrograms
(EGMs), device markers, and electrocardiogram (ECG)
data was placed for the duration of the study proced-
ures. Initial algorithm parameter settings, including
accelerometer vector combination, A3 end time, A3
threshold, and A4 threshold, were set by the algorithm
auto-setup feature during VVI-50 pacing. Following
auto-setup, the algorithm parameters were adjusted to
optimize A4 detection, if needed.
After the algorithm parameters were set, the pac-
ing mode was programmed to VDD, and the patient
rested in a supine or sitting position for approxi-
mately 20 min. Following the resting period, the pa-
tient assumed a series of postures (supine, lying on
right side, lying on left side, sitting, and standing) for
2 min each. In addition, patients walked at a
comfortable and vigorous pace for 2 min to promote
an activity mode switch.
Echocardiograms were collected from each patient
during both VVI and VDD pacing following a stan-
dardized echo protocol. An echocardiography core
laboratory (United Heart and Vascular Clinic, St. Paul,
Minnesota), blinded to patient and pacing mode,
measured the left ventricular outflow (LVOT)
velocity-time integral (VTI) during 6 cardiac cycles in
each pacing mode.
In addition to the preceding procedures, newly
implanted patients had the algorithm downloaded to
their devices; they underwent Holter monitoring and
completed the auto-setup procedure immediately
following device implantation. For newly implanted
patients, the MARVEL 2 software was removed
following each evaluation time point. Evaluation of
algorithm performance in these patients allowed the
MARVEL 2 features to be tested at multiple points in
the device life cycle.
ENDPOINTS. The primary efficacy endpoint was
defined as a paced or sensed ventricular beat within
300 ms following a surface ECGconfirmed P-wave for
at least 70% of ECGconfirmed P-waves. For each pa-
tient, the primary efficacy endpoint was evaluated
during the auto-setup phase, which occurred during
VVI pacing, and during the resting phase, which
occurred during VDD pacing. The primary safety
endpoint was defined as freedom from pauses lasting
>2 cardiac cycles (defined by the programmed lower
rate interval) and freedom from episodes of
oversensing-induced tachycardia >100 beats/min for
>3 min. The secondary endpoint was LVOT-VTI as
obtained from echocardiogram while the algorithm
was programmed to VVI mode and VDD mode. All
enrolled patients who had the investigational algo-
rithm was downloaded to their devices were assessed
for the primary safety endpoint, whereas the subset of
patients with complete AV block and normal sinus
function were evaluated for the primary efficacy and
secondary endpoints.
STATISTICAL METHODS. A priori determination of
sample size indicated that 35 patients with normal
sinus node function and complete AV block would
provide >90% power to test the primary efficacy
endpoint, assuming $50% of patients would have
discordant results between pacing modes and $90%
of discordant results would favor algorithm-mediated
VDD pacing. A sample size of 70 patients (with any
predominant rhythm) provided 90% power to test the
primary safety endpoint against a predefined perfor-
mance goal of 87%, assuming the true underlying
endpoint rate exceeded 98%. Finally, a sample size of
35 patients with normal sinus node function and
complete AV block provided 89% power to test for a
difference in LVOT-VTI between pacing modes,
assuming a mean difference that favored algorithm
VDD pacing of 2.1  3.8 cm. All sample size calcula-
tions assumed a 2-sided type I error rate of 5%.
Each patient’s predominant heart rhythm was
determined as complete AV block with normal sinus
function, intact AV conduction, or other (e.g., atrial
arrhythmias, sinus node dysfunction, other AV block)
based on PR intervals (during auto-setup) and PP in-
tervals during the auto-setup and resting phases.
For each cardiac cycle, AV synchrony status was
determined as described in the Online Appendix. AV
synchrony percentage was calculated for each patient
Steinwender et al. J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 6 , N O . 1 , 2 0 2 0
Atrioventricular Synchronous Leadless Pacing J A N U A R Y 2 0 2 0 : 9 4 – 1 0 6
96
during the auto-setup and resting phases by dividing
the number of synchronous cycles by the total num-
ber of cardiac cycles. The primary efficacy analysis
cohort included patients with complete AV block
and normal sinus rhythm who had at least 500
evaluable cardiac cycles during the auto-setup and
resting phases. For newly implanted patients, the
pre-hospital discharge visit was used. McNemar’s test
was used to compare the proportion of patients
with $70% AV synchrony during VVI and VDD pacing,
respectively. In addition, AV pacing percentages and
atrial detection rates were compared between pacing
modes and estimated during each posture and ma-
neuver using logistic regression models that incor-
porated generalized estimating equations to account
for correlation in algorithm performance within each
patient. Similar models were used to compare AV
Synchrony percentage between the pre-hospital
discharge and 1-month study visits for newly
implanted patients. Due to skewness observed in AV
synchrony proportions of individual patients, both
the expected AV synchrony proportion based on the
logistic model and the median percentage were
reported.
Holter recordings fromall patientswere assessed for
the primary safety endpoint using both programmatic
and manual review. The proportion of patients who
met the primary safety endpoint was compared with
the performance goal using an exact binomial test.
A paired Student’s t-test was used to evaluate the
change in mean LVOT-VTI between VVI and VDD
modes in patients with complete AV block and normal
sinus rhythm after averaging LVOT-VTI across
measurements.
Type I error was controlled at the 0.05 level for
analysis of the primary and secondary endpoints us-
ing a hierarchical closed testing procedure.
In a post hoc analysis, sinus rates computed be-
tween successive PP intervals were compared be-
tween the last 5 min of VVI and VDD pacing during
the auto-setup and resting periods in patients who
were evaluated for the primary efficacy endpoint
TABLE 1 Patient Baseline Characteristics
Enrolled
(n ¼ 77)
Downloaded MARVEL 2
Software
(n ¼ 75)
Evaluable for Primary
Efficacy Objective
(n ¼ 40)
Age, yrs
Mean  SD 77.6  11.8 77.5  11.8 76.7  12.9
Median 81.0 81.0 80.0
Female 31 (40.3) 30 (40.0) 22 (55.0)
Months from Micra implantation
Mean  SD 13.7  14.5 13.8  14.6 14.6  16.6
Median 9.7 9.7 9.3
Comorbidities
Hypertension 53 (68.8) 52 (69.3) 28 (70.0)
Atrial fibrillation 14 (18.2) 14 (18.7) 3 (7.5)
Diabetes 14 (18.2) 13 (17.3) 6 (15.0)
Coronary artery disease 23 (29.9) 23 (30.7) 8 (20.0)
COPD 7 (9.1) 7 (9.3) 4 (10.0)
Dialysis 3 (3.9) 3 (4.0) 1 (2.5)
Device location
RV apex 12 (15.6) 12 (16.0) 8 (20.0)
RV high septum 11 (14.3) 11 (14.7) 7 (17.5)
RV mid-septum 27 (35.1) 26 (34.7) 11 (27.5)
RV low septum 12 (15.6) 12 (16.0) 8 (20.0)
RVOT 12 (15.6) 12 (16.0) 4 (10.0)
Other 2 (2.6) 2 (2.7) 2 (5.0)
Not reported 1 (1.3) 0 (0.0) 0 (0.0)
Predominant rhythm*
Complete AV block with normal sinus function 40 (51.9) 40 (53.3) 40 (100.0)
Intact AV conduction 18 (23.4) 18 (24.0) 0 (0.0)
Other rhythm 15 (19.5) 15 (20.0) 0 (0.0)
Indeterminate rhythm† 2 (2.6) 2 (2.7) 0 (0.0)
Patient exited before software download 2 (2.6) 0 (0.0) 0 (0.0)
Values are mean  SD and n (%). *Predominant rhythm at pre-hospital discharge visit for 10 newly implanted patients. †Noise on surface electrocardiographic signal prevented
assessment of predominant rhythm.
AV ¼ atrioventricular; COPD ¼ chronic obstructive pulmonary disease; RV ¼ right ventricular; RVOT ¼ right ventricular outflow tract.
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using a repeated measures analysis of variance
model. Statistical analyses were performed using SAS
version 9.4 (SAS Institute, Cary, North Carolina) or R
software (R Foundation, Vienna, Austria).
RESULTS
PATIENTS. A total of 77 patients from 12 centers in
Europe, Malaysia, Hong Kong, and the United States
were enrolled in the MARVEL 2 study. Of the
77 enrolled patients, 75 devices received the software
download, and 74 (96%) patients completed the study
procedures, with 1 exiting after the software down-
load, but before completing the echocardiographic
procedure to evaluate LVOT-VTI. Average age of the
enrolled patients was 77.6  11.8 years (range 21 to 94
years), and 31 (40%) patients were women. Patients
had been implantedwith aMicra device for amedian of
9.7 months (range 0 to 62.1 months) (Table 1). Ten
patients were enrolled on the day of implantation and
were considered newly implanted patients. The most
common primary pacing indication was third-degree
AV block without atrial arrhythmias (n ¼ 47; 61.0%).
Of the 77 enrolled patients, 40 (51.9%) had a predom-
inant rhythm of complete AV block with normal sinus
function duringHoltermonitoring during theMARVEL
2 procedure (pre-hospital discharge visit for newly
implanted patients) and were eligible for inclusion in
the primary efficacy objective (Online Figure S2). The
remaining patients had a predominant rhythm of
intact AV conduction (n ¼ 18; 23.4%), other rhythm
(n ¼ 15; 19.5%), or indeterminate rhythm due to poor
ECG quality (n ¼ 2; 2.6%) and were not included in the
primary efficacy objective analysis.
EFFICACY RESULTS. All 40 patients with a predom-
inant rhythm of complete AV block with normal sinus
rhythm were included in the primary efficacy anal-
ysis. AV synchrony percentage increased from an
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Atrioventricular (AV) synchronous pacing percentage during auto-setup (VVI-50 mode) and resting (VDD mode) in 40 patients with complete
AV block and normal sinus rhythm. Gray lines indicate individual patients. Blue line connects average AV synchrony percentage and the red
line connects medians. Error bars are 95% confidence intervals. Black dashed line is the primary objective of 70%. During VVI-50 pacing, 0%
of patients had $70% AV synchrony, during VDD pacing 95% had $70% AV synchrony (p < 0.001).
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FIGURE 1 Distribution of P-V Intervals
Distribution of P-V intervals during auto-setup (VVI-50 mode) and during resting (VDD mode) for 4 patients with percentage of atrioventricular
(AV) synchrony during VDD pacing ranging from 99.7% to 33.4%. Red dashed line indicates 300 ms.
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average of 26.8% (95% confidence interval [CI]: 26.2%
to 27.5%; median: 26.9%) to 89.2% (95% CI: 84.8% to
92.5%; median: 94.3%) during VVI-50 and VDD pac-
ing, respectively (Central Illustration). Zero patients
had $70% AV synchrony during VVI-50 pacing,
whereas 38 (95%) had $70% AV synchrony during
algorithm-mediated VDD pacing (p < 0.001 for pro-
portion of patients with $70% synchrony). The dis-
tribution of P-wave to V-event (PV) intervals during
VVI-50 pacing were generally uniform between
0 and 1,200 ms, whereas they were peaked and
centered at values <300 ms during VDD pacing
(Figure 1). The 2 patients who failed to meet the pri-
mary efficacy endpoint during VDD pacing were from
2 different centers and had AV synchrony percentages
of 68.6% and 33.4%, respectively. The first patient
had low and variable amplitude A4 signals. The
accelerometer signals for the second patient were
exemplified by small signals related to both atrial and
ventricular contraction (i.e., small A4 and A1 signals,
respectively) and large signals during passive ven-
tricular filling (A3). Notably, this patient had a history
of repaired tetralogy of Fallot in childhood with pul-
monary valve replacement.
During posture and maneuver testing assessed
over 2 min each among all 40 patients, AV synchrony
ranged from 89.2% during the resting period to 69.8%
while standing (Figure 2). During the resting period,
the ability of the rate smoothing operation to main-
tain synchrony during intermittent A4 undersensing
allowed the AV synchrony percentage to exceed
the A4 detection rate (89.2% vs. 80.3%)
(Online Figure S3). There was no association between
AV synchrony percentage and time since implanta-
tion (Online Figure S4). There was also no evidence to
suggest that the percentage of AV synchrony differed
by physician-reported Micra implantation location
(p ¼ 0.287).
Among patients with intact AV conduction, the
mean AV synchrony percentage was 74.8% (95% CI:
53.6% to 88.4%; median 98.9%) during VVI-50 pacing
and 79.6% (95% CI: 59.1% to 91.3%; median: 99.7%)
during VDD pacing. There were 2 patients with long
PV intervals, with >97% of PV intervals >300 ms (pre-
specified definition of synchrony); therefore, both
patients had <3% AV synchrony in both pacing
modes. Of the 15 patients with other rhythms, 7 had
visible P waves confirmed and/or detected. The
FIGURE 2 AV Synchrony Percentage by Maneuver
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remaining 8 had no visible P-waves due to atrial
fibrillation or atrial flutter. For the 7 patients with
other rhythms and identifiable P-waves, mean AV
synchrony increased from 41.3% (95% CI: 24.6% to
60.3%; median: 37.7%) during VVI-50 pacing to 70.2%
(95% CI: 42.3% to 88.4%; median: 89.3%) during VDD
pacing. In patients with atrial fibrillation, the A4
accelerometer signal was of low amplitude, and there
was infrequent sensing, which resulted in median
ventricular pacing at the lower rate (50 beats/min). In
the patient with atrial flutter, the accelerometer
signal was intermittently detected, which resulted in
ventricular pacing at 67 beats/min (interquartile
range: 66 to 67 beats/min). Among the 10 newly
implanted patients, the mean AV synchrony per-
centage was not significantly different between the
pre-hospital discharge and 1-month visit (p ¼ 0.329).
For additional details on algorithm performance in
the newly implanted patients, refer to the Online
Appendix and Online Figure S5.
Among the 40 patients with complete AV block and
normal sinus rhythm, 39 had paired echocardio-
graphic data available for analysis. LVOT-VTI as a
proxy of left ventricular stroke volume increased by
FIGURE 3 LVOT-VTI During VVI-50 and VDD Pacing
Left ventricular outflow tract velocity-time integral (LVOT-VTI) (cm) during VVI-50 and VDD pacing in 39 patients with complete AV block and
normal sinus function. (Left) LVOT-VTI during VVI-50 and VDD pacing for individual patients (gray lines) and on average (blue lines). (Right)
Absolute change in LVOT-VTI during VDD relative to VVI-50 pacing for individual patients (red circles) and on average (blue circle). Error bars
represent 95% confidence intervals. BPM ¼ beats per minute.
J A C C : C L I N I C A L E L E C T R O P H Y S I O L O G Y V O L . 6 , N O . 1 , 2 0 2 0 Steinwender et al.
J A N U A R Y 2 0 2 0 : 9 4 – 1 0 6 Atrioventricular Synchronous Leadless Pacing
101
1.7 cm (95% CI: 0.7 to 2.7 cm; p ¼ 0.002) or 8.8  15.4%
during VDD pacing from a baseline average of 22.7 cm
(95% CI: 21.0 to 24.4 cm) during VVI pacing (Figure 3).
Similar results were observed for the 15 patients with
other predominant heart rhythms (mean increase:
2.4 cm; 95% CI: 0.9 to 4.0 cm, during VVI pacing over
an average 22.0 cm during VDD pacing).
For the 40 patients with complete AV block and
normal sinus rhythm, the sinus rate decreased from
an average of 73.0 beats/min during VVI-50 pacing to
66.2 beats/min during VDD pacing (p < 0.001)
(Figure 4).
MODE SWITCHING. All Holter files from the 75 pa-
tients who had the algorithm was downloaded to their
devices were reviewed to identify both AV conduc-
tion and activity mode switches. During the entire
Holter recording period, there were 470 AV conduc-
tion mode switches in 73 patients. During these mode
switches, the pacing mode remained in VVI-40, pro-
moting intrinsic AV conduction and functioning as
intended. Figure 5A shows an example of a patient
with intermittent third-degree AV block with an AV
mode switch from VVI-40 to VDD when AV block
occurred. There were 41 activity mode switch
FIGURE 4 Sinus Rate During VVI-50 and VDD Pacing
Sinus rate during VVI-50 and VDD pacing in 40 patients with complete AV block and normal sinus function. (Left) Sinus rate during VVI-50 and
VDD pacing for individual patients (gray lines) and on average (blue lines). (Right) Change in sinus rate during VDD relative to VVI-50 pacing
for individual patients (red circles) and on average (blue circle). Error bars represent 95% confidence intervals. BPM ¼ beats per minute; other
abbreviation as Figure 1.
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episodes observed in 26 patients. Among the 41 ac-
tivity mode switches, the median duration of VVIR
pacing was 191.7 s. Figure 5B shows an example of an
activity mode switch in a patient with complete AV
block and normal sinus rhythm. Examination of each
activity mode switch episode showed appropriate
pacing support during the hall walk exercise and the
activity mode switch operated as intended. The
automatic algorithm was effective in choosing the
appropriate accelerometer vector(s), A3 threshold,
and A4 threshold, and adjusted the parameters
throughout the study (see Online Appendix).
FIGURE 5 AV Conduction Mode Switch and Activity Mode Switch
(A) AV conduction mode switch in patient with intermittent third-degree AV block. Before the mode switch at 2,884 s, the patient exhibits AV
conduction in VVI-40 mode. The patient then goes into second-degree AV block, and the device mode-switches to VDD. Two cycles after the
mode switch, the device begins tracking the atrium in VDD mode. (B) Activity mode switch in patient with complete AV block and normal sinus
rhythm. During the standing and/or walking maneuvers, good AV synchrony is indicated by the similarity of median heart rate (HR) and sinus
rate. Mode switch to VVIR occurs when the sensor rate diverges from the pacing rate. The sensor rate decreases to the median HR and gradually
increases to minimize large rate changes. After the activity ceases, the mode returns to VDD promoting AV synchronous pacing. ADL ¼ activities
of daily living; AS ¼ atrial sense; ECG ¼ electrocardiogram; MS ¼ mode switch; VE ¼ ventricular end; VEGM ¼ ventricular electrogram;
VP ¼ ventricular pace; VS ¼ ventricular sense; other abbreviations as in Figures 1 and 4.
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SAFETY RESULTS. Among the 75 patients who had
the algorithm downloaded, there were a total of 95
Holter recordings (newly implanted patients had 3
Holter recordings) that included 647,384 cardiac cy-
cles for the primary safety endpoint analysis. There
were no instances of ventricular pauses and no in-
stances of oversensing-induced tachycardia; there-
fore, all 75 patients (100%) whose devices were
downloaded with the algorithm met the primary
safety endpoint. The lower 2-sided CI was 95.2%,
which exceeded the performance goal of 87%; there-
fore, the primary safety objective was met (p < 0.001).
Among the 77 enrolled patients, 6 adverse events
were reported in 5 patients. Of the 6 adverse events,
none were considered by the investigator to be
related to the algorithm or procedures. There was 1
event (right atrial hematoma) that was discovered
during echocardiography and was considered to have
a probable relationship to the Micra device. This
adverse event was noted 4.8 months after Micra im-
plantation on the day of the MARVEL 2 study pro-
cedures and was considered serious by the
investigator. The patient was hospitalized for obser-
vation, but no clinical actions were reported during
the course of the study.
DISCUSSION
There were several important findings from this study
of AV synchronous pacing in patients with single-
chamber right ventricular leadless pacemakers
capable of accelerometer-based atrial sensing. First,
the automated, enhanced MARVEL 2 algorithm
robustly tracked mechanical atrial contraction and
facilitated AV synchrony. Specifically, the study
intervention improved median AV synchrony from
27% with VVI pacing to 94% in VDD pacing mode, with
95% of the cohort (38 of 40 patients with complete AV
block) achieving $70% AV synchronous pacing. Sec-
ond, the VDD pacing algorithm improved ventricular
performance 9% asmeasured by LVOT-VTI, a proxy for
left ventricular stroke volume. Finally, during the
study period, the algorithm proved safe, with no in-
stances of pauses or oversensing-induced tachycardia,
regardless of predominant heart rhythm.
AV synchrony was best achieved at rest. Mainte-
nance of high AV synchrony at high sinus rates could
be complicated by superposition of accelerometer
signals related to the atrial contraction with early
periods of ventricular filling. Sitting and standing
postures demonstrated a decrease in AV synchrony,
but the mean value remained $70%. The reasons for
the reduction in AV synchrony could be related to
orthostatic tachycardia and a slight decrease in A4
signal due to decreased venous return during the
postural change and the limited 2-min postural
testing period. We found no evidence of a relation-
ship between time since implantation and the ability
for the algorithm to produce a high percentage of AV
synchrony. Specifically, the performance of the algo-
rithm did not appear to have diminished efficacy in
newer implantations versus long-term implantations.
These encouraging results reaffirmed the observa-
tions from those previously reported in the MARVEL
trial, which also demonstrated an increase in AV
synchrony and stroke volume with VDD pacing (9).
A preliminary proof-of-concept study that used a
simpler algorithm reported an average AV synchrony
of 80.0% in patients with AV block during VDD pacing,
with 72.7% having$70% synchrony (9). Following this
study, enhancements were made to the algorithm to
improve detection in patients with low A4 signals,
including an enhanced filter for atrial signal sensing
and the ability to use a combination of 2 different
accelerometer vectors. These enhancements, along
with auto-adjusting detection parameters, might
explain the higher proportion of patients with $70%
AV synchrony observed in the MARVEL 2 study.
Cardiac output is reduced in patients with com-
plete AV block and slow ventricular response
compared with normal resting heart rates, despite
compensatory mechanisms, including increased si-
nus rates and stroke volumes (11). It is a well-known
phenomenon that restoration of heart rate with a
pacemaker to a more physiological level results in
decreased sympathetic tone and lower sinus rates.
The significantly lower sinus rate observed with VDD
pacing compared with VVI-50 pacing likely reflects a
similar physiological phenomenon, with more physi-
ological AV synchrony and ventricular rates reducing
sympathetic tone and sinus rates. The observed
reduction in sinus rates and the improvement in
LVOT-VTI demonstrated the positive impact of AV
synchronous pacing in patients with complete AV
block.
Inhibition of ventricular pacing in patients with
intrinsic AV conduction and sensor-based VVIR pac-
ing during exercise were reliably delivered by 2
different mode-switching algorithms implemented in
the MARVEL 2 algorithm. The intact AV conduction
mode switch (Figure 5A) regularly checks for intrinsic
AV conduction. This feature was developed to limit
pacing to the minimum amount necessary, and in
turn, to prevent conflicts between pacing triggered by
the algorithm and the patient’s intrinsic sinus
rhythm. By reducing unnecessary pacing, it helps to
prevent right ventricular pacinginduced cardiomy-
opathy and to extend battery life.
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Although AV synchrony was excellent at rest, it
decreased during physical activity. Two phenomena
contributed to this effect by hampering detection of
atrial contraction. First, an increase in heart rate with
these maneuvers led to fusion of the atrial and ven-
tricular components of the accelerometer signals.
Second, additional accelerations caused by body
motion were superimposed on the intra-cardiac sig-
nals. To overcome the decreased AV synchrony dur-
ing exercise, the activity mode switch (Figure 5B) was
implemented in the MARVEL 2 algorithm. When
detecting a significant difference between the tracked
sinus rate and heart rate suggested by the pace-
maker’s rate response function, VDD mode automat-
ically switched to VVIR, and the pacing rate was
slowly raised to the sensor rate level. Loss of AV
synchrony due to activity mode switching might be
seen as a downside of the MARVEL 2 algorithm;
however, it was previously shown that the heart rate
itself contributed much more to cardiac output at
higher heart rates than AV synchrony (12,13). Impor-
tantly, none of the patients under investigation re-
ported adverse events due to intermittent lack of AV
synchrony or VVIR pacing during exercise.
The algorithm demonstrated a clear increase of AV
synchrony compared with VVI mode, although it did
not achieve 100% AV synchrony, similar to trans-
venous VDD pacemakers (14,15). To the best of our
knowledge, the optimal percentage of AV synchrony
required to maintain benefit and minimize pacemaker
syndrome has not been characterized. It is plausible
that 100% AV synchrony might not be required to
allow normal exercise capacity and lifestyle. A lower
percentage of AV synchrony might be sufficient,
especially with the substantially lower complications
associated with a leadless device. In the Micra global
clinical trials, in which only VVI(R) pacing was
delivered, approximately one-third of patients had
normal sinus rhythm, which suggests that physicians
were willing to sacrifice synchrony for the benefits of
leadless pacemakers (3). Therefore, selection of this
pacing mode will require a consideration of the ben-
efits of leadless pacing versus the patient’s need for
even higher degrees of AV synchrony.
STUDY LIMITATIONS. The observational period and
sample size were limited andmight not reflect the total
variability of use conditions in the long term. Thus,
results must be confirmed in larger patient pop-
ulations with longer follow-up. The downloadable
nature of the algorithm increased current drain by
approximately 100, precluding continuous long-
term AV synchrony evaluation or the use of the
algorithm in existing implanted Micra devices.
Incorporation of the algorithm into the electronics of
an upgraded leadless device could reduce the current
drain, allowing long-term implantation. For such a
future device, it will be important to assess the
robustness of ambulatory AV synchrony over real-
world conditions and demonstrate that AV synchrony
is maintained continuously over time. Symptomatic
and functional assessment data were not collected;
therefore, determination of the precise amount of AV
synchrony required to avoid symptoms or maintain
appropriate cardiac performance was not assessed.
CONCLUSIONS
Accelerometer-based atrial sensing with a novel,
automated, enhanced algorithm significantly
improved AV synchrony and stroke volume in patients
with sinus rhythm and AV block implanted with a
single-chamber leadless pacemaker in the right
ventricle.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The enhanced
MARVEL 2 algorithm allowed for AV synchronous ventricular
pacing with a leadless pacemaker in patients with normal sinus
activity and complete heart block. The algorithm worked safely
and robustly, even when changing posture or during physical
activity. An increase in stroke volume was observed with AV
synchronous pacing using the enhanced MARVEL 2 algorithm
compared with VVI pacing.
TRANSLATIONAL OUTLOOK: Until now, leadless pacemakers
have only been capable of single-chamber pacing (VVI/R). If
implemented in clinical practice, this new technology will help
to further expand the spectrum of patients who might be
eligible for leadless pacing.
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APPENDIX For expanded Methods and
Results sections as well as supplemental
figures, please see the online version of this
paper.
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